Oncology
Peritoneal Carcinoma
0
Pipeline Programs↗
0
Active Trials↗
1
Companies Involved↗
Peritoneal Carcinoma is an early-stage landscape with 0 programs across 1 company. The most active players are Takeda.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
4
clinical trials
Completed3 · 75%
Terminated1 · 25%
Clinical Trials
Trial Activity
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
Completed·—·Phase 2·NCT00768144·36 enrolled
Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
Completed·—·Phase 2·NCT01519869·28 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)